CY1118526T1 - Παραγωγα διϋδροπυραζολοπυριμιδινονης - Google Patents

Παραγωγα διϋδροπυραζολοπυριμιδινονης

Info

Publication number
CY1118526T1
CY1118526T1 CY20171100129T CY171100129T CY1118526T1 CY 1118526 T1 CY1118526 T1 CY 1118526T1 CY 20171100129 T CY20171100129 T CY 20171100129T CY 171100129 T CY171100129 T CY 171100129T CY 1118526 T1 CY1118526 T1 CY 1118526T1
Authority
CY
Cyprus
Prior art keywords
group
compounds
dydropyrozolopyrimininone
products
lower alkyl
Prior art date
Application number
CY20171100129T
Other languages
English (en)
Inventor
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Makoto Bamba
Keiji Takahashi
Hidetomo Furuyama
Yasuhiro Goto
Takeshi Sagara
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Original Assignee
Msd K.K.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118526(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd K.K. filed Critical Msd K.K.
Publication of CY1118526T1 publication Critical patent/CY1118526T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση σχετίζεται με ενώσεις ενός γενικού χημικού τύπου (I): όπου το Α1 επιλέγεται από τον ακόλουθο χημικό τύπο (aa1)· το R1 είναι ομάδα κατώτερου αλκενυλίου ή ομάδα κατώτερου αλκυνυλίου· το R2 είναι ομάδα φαινυλίου, πυριδυλίου ή θειενυλίου· τα R5 και R6 είναι άτομο υδρογόνου, ομάδα κατώτερου αλκυλίου ή ομάδα υδροξυ- κατώτερου αλκυλίου, κλπ. Οι ενώσεις της εφεύρεσης έχουν εξαιρετική ανασταλτική επίδραση της κινάσης Weel και είναι επομένως χρήσιμες στο πεδίο των φαρμάκων, ιδιαίτερα στην αγωγή διαφόρων καρκίνων.
CY20171100129T 2006-04-27 2017-01-27 Παραγωγα διϋδροπυραζολοπυριμιδινονης CY1118526T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059416 WO2007126128A1 (ja) 2006-04-27 2007-04-25 ジヒドロピラゾロピリミジノン誘導体

Publications (1)

Publication Number Publication Date
CY1118526T1 true CY1118526T1 (el) 2017-07-12

Family

ID=38655640

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100973T CY1111069T1 (el) 2006-04-27 2010-10-27 Παραγωγα διυδροπυραζολοπυριμιδινονης
CY20171100129T CY1118526T1 (el) 2006-04-27 2017-01-27 Παραγωγα διϋδροπυραζολοπυριμιδινονης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100973T CY1111069T1 (el) 2006-04-27 2010-10-27 Παραγωγα διυδροπυραζολοπυριμιδινονης

Country Status (39)

Country Link
US (4) US7834019B2 (el)
EP (2) EP2017278B1 (el)
JP (2) JP4513919B2 (el)
KR (1) KR101409161B1 (el)
CN (1) CN101432284B (el)
AR (1) AR060635A1 (el)
AT (1) ATE475662T1 (el)
AU (1) AU2007244185B2 (el)
BR (1) BRPI0710081A2 (el)
CA (1) CA2650119C (el)
CR (1) CR10359A (el)
CY (2) CY1111069T1 (el)
DE (1) DE602007008085D1 (el)
DK (2) DK2017278T3 (el)
DO (1) DOP2007000084A (el)
EC (1) ECSP088812A (el)
ES (2) ES2348751T3 (el)
GT (1) GT200800211A (el)
HK (1) HK1132498A1 (el)
HN (1) HN2008001532A (el)
HR (2) HRP20100563T1 (el)
HU (1) HUE032987T2 (el)
IL (1) IL194367A (el)
LT (1) LT2017278T (el)
MA (1) MA30428B1 (el)
MX (1) MX2008013063A (el)
MY (1) MY145408A (el)
NO (1) NO341617B1 (el)
NZ (1) NZ571196A (el)
PE (1) PE20080695A1 (el)
PL (2) PL2017278T3 (el)
PT (2) PT2016080E (el)
RU (1) RU2437885C2 (el)
SI (2) SI2017278T1 (el)
SV (1) SV2009003060A (el)
TW (1) TWI409262B (el)
UA (1) UA96152C2 (el)
WO (2) WO2007126122A1 (el)
ZA (1) ZA200807748B (el)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US8198281B2 (en) * 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
WO2009151997A1 (en) * 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
AU2009325400A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2010098367A1 (en) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
WO2011027800A1 (en) * 2009-09-02 2011-03-10 Banyu Pharmaceutical Co.,Ltd. Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
US9207360B2 (en) * 2011-04-27 2015-12-08 Zeno Corporation Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
PL2925888T3 (pl) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
EP3235505B1 (en) * 2014-12-17 2020-05-06 Delta-Fly Pharma, Inc. Pharmaceutical composition for treatment or palliation of elderly or end-stage cancer patient
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
TW201706258A (zh) 2015-04-17 2017-02-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
WO2017038838A1 (ja) * 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
CN106271589B (zh) * 2016-06-23 2018-12-28 中山市美捷时包装制品有限公司 一种用于预装阀杆、弹簧、垫片的组装设备
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
SI3512833T1 (sl) 2016-09-15 2020-11-30 Boehringer Ingelheim International Gmbh Heteroarilne karboksamidne spojine kot inhibitorji RIPK2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
CN110198943B (zh) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
JP7140337B2 (ja) * 2017-03-23 2022-09-21 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド ピラゾロ［３，４－ｄ］ピリミジン－３－オンの大環状誘導体、その医薬組成物及び応用
WO2018183891A1 (en) 2017-03-31 2018-10-04 Cascadian Therapeutics Combinations of chk1- and wee1 - inhibitors
TW201910335A (zh) * 2017-08-01 2019-03-16 美商薩諾皇家麥爾斯通有限責任公司 1,2-二氫-3H-吡唑并[3,4-d]嘧啶-3-酮類似物
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CA3080842A1 (en) * 2017-11-01 2019-05-09 Shijiazhuang Sagacity New Drug Development Co., Ltd. Macrocyclic compound serving as weel inhibitor and applications thereof
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) * 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
CN117285532A (zh) * 2018-03-09 2023-12-26 里科瑞尔姆Ip控股有限责任公司 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
KR20210141659A (ko) 2019-03-22 2021-11-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
EP3952877A4 (en) 2019-04-09 2022-12-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
US20220220120A1 (en) 2019-04-30 2022-07-14 Shijiazhuang Sagacity New Drug Development Co., Ltd Crystal form of wee1 inhibitor compound and use thereof
CA3145344A1 (en) 2019-06-28 2020-12-30 Shanghai Pharmaceuticals Holding Co., Ltd. Pyrazolopyrimidine compound, preparation method for same and applications thereof
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
JP2022554157A (ja) 2019-10-25 2022-12-28 アストラゼネカ・アクチエボラーグ がんを処置する方法
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171128A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
KR20240004584A (ko) 2021-04-29 2024-01-11 노파르티스 아게 탈유비퀴티나아제-표적화 키메라 및 관련된 방법
JP2024515318A (ja) 2021-04-30 2024-04-08 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｗｅｅ－１阻害剤としての縮合環状化合物、その調製方法およびその使用
CN115403582A (zh) 2021-05-28 2022-11-29 江苏天士力帝益药业有限公司 Wee1抑制剂及其用途
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
WO2023072301A1 (zh) * 2021-11-01 2023-05-04 正大天晴药业集团股份有限公司 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN116462687A (zh) * 2022-01-18 2023-07-21 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
TW202404977A (zh) * 2022-07-15 2024-02-01 大陸商映恩生物製藥（蘇州）有限公司 一種嘧啶并五員雜環化合物、其製備方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
ES2137932T3 (es) 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
AU2003224341A1 (en) 2002-04-26 2003-11-10 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US7407962B2 (en) * 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CA2569530C (en) 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co.,Ltd. Thienopyrazole derivative having pde 7 inhibitory activity
ES2411975T3 (es) 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
EP2017278B1 (en) 2016-11-02
UA96152C2 (en) 2011-10-10
ES2348751T3 (es) 2010-12-13
ZA200807748B (en) 2009-10-28
EP2016080B1 (en) 2010-07-28
HUE032987T2 (en) 2017-11-28
EP2016080A4 (en) 2009-05-13
CA2650119A1 (en) 2007-11-08
JP5167291B2 (ja) 2013-03-21
SI2017278T1 (sl) 2017-05-31
ES2609087T3 (es) 2017-04-18
SI2016080T1 (sl) 2011-03-31
WO2007126128A1 (ja) 2007-11-08
DE602007008085D1 (en) 2010-09-09
IL194367A0 (en) 2009-08-03
GT200800211A (es) 2009-04-07
WO2007126122A1 (en) 2007-11-08
CR10359A (es) 2009-02-19
US8791125B2 (en) 2014-07-29
ECSP088812A (es) 2008-11-27
JP2010132689A (ja) 2010-06-17
EP2017278A4 (en) 2009-04-22
NO341617B1 (no) 2017-12-11
MY145408A (en) 2012-02-15
CA2650119C (en) 2017-03-14
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
US20140303178A1 (en) 2014-10-09
SV2009003060A (es) 2009-04-28
NO20084968L (no) 2008-11-26
PT2016080E (pt) 2010-10-14
KR101409161B1 (ko) 2014-06-19
US7935708B2 (en) 2011-05-03
PE20080695A1 (es) 2008-06-28
DK2017278T3 (en) 2017-02-13
JPWO2007126128A1 (ja) 2009-09-17
IL194367A (en) 2014-12-31
EP2017278A1 (en) 2009-01-21
TWI409262B (zh) 2013-09-21
AU2007244185B2 (en) 2012-10-04
CY1111069T1 (el) 2012-05-23
US20070254892A1 (en) 2007-11-01
CN101432284B (zh) 2012-08-15
AU2007244185A1 (en) 2007-11-08
TW200811176A (en) 2008-03-01
HRP20161763T1 (hr) 2017-02-24
PT2017278T (pt) 2017-01-03
ATE475662T1 (de) 2010-08-15
HRP20100563T1 (hr) 2010-11-30
US20100063024A1 (en) 2010-03-11
CN101432284A (zh) 2009-05-13
MX2008013063A (es) 2008-12-16
NZ571196A (en) 2011-03-31
JP4513919B2 (ja) 2010-07-28
US20110189130A1 (en) 2011-08-04
KR20090017491A (ko) 2009-02-18
RU2437885C2 (ru) 2011-12-27
DK2016080T3 (da) 2010-11-22
BRPI0710081A2 (pt) 2011-08-02
LT2017278T (lt) 2017-01-25
HK1132498A1 (en) 2010-02-26
DOP2007000084A (es) 2007-12-31
PL2016080T3 (pl) 2011-03-31
PL2017278T3 (pl) 2017-10-31
EP2016080A1 (en) 2009-01-21
US7834019B2 (en) 2010-11-16
AR060635A1 (es) 2008-07-02
HN2008001532A (es) 2009-06-10

Similar Documents

Publication Publication Date Title
CY1118526T1 (el) Παραγωγα διϋδροπυραζολοπυριμιδινονης
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1118448T1 (el) Παραγωγο δικυκλοανιλινης
CY1113486T1 (el) Συντηγμενες δικυκλικες πυριμιδινες
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
DK2250172T3 (da) Pyrrolopyrazinkinaseinhibitorer
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
UY30050A1 (es) Derivados de pirimido-oxazinil-fenilo, sales de los mismos, composiciones, preparaciones y aplicaciones
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1111922T1 (el) 1-ετεροκυκλυλσουλφονυλ, 2-αμινομεθυλ, 5-(ετερο-)αρυλ υποκατεστημενα 1-η-πυρρολιου παραγωγα ως αναστολεις εκκρισης οξεος
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
NZ710052A (en) Novel pyrazol derivatives
IL204437A (en) History of aryl cyclic profile and their use
ATE438402T1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
EA200702002A1 (ru) Замещённые производные пиразолилоксифенила, применяемые в качестве гербицидов
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
ATE470665T1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
ATE445593T1 (de) Acetylenderivate
ECSP088677A (es) Piperazinas y piperidinas como potenciadores 157 del mglur5
NO20076333L (no) Anvendelse av thiazolderivater og analoge i behandling av kreft
CY1113812T1 (el) Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
UA107689C2 (en) 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES